The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
"I've not heard her say and to do deals on them at the earliest possible moment on either Modirope or ImmunoBody she looks to have fallen in love with iSCIB+ now too:) the plan clearly is get them through ph2s then partner them ... errrr and if that is not the plan and in fact the door is not only wide open but they are bashing at the doors of over 20 companies I can think of straight away even though there are lots more why not say so!"
To be fair to crumbs, he has a point here, especially the falling in love bit, the company has gone through a number of chairman, the one common thread is Lindy (but yes I appreciate her science is why the company exists in the first place).
Hopefully Cossery though has now finally bought in a new more cut throat approach, commercially speaking, and redmile and vulpes will finally (and soon) want their payback for their investment.
Saying all that though, the extension of options means the closed period notion seems to be both very intriguing and logical. No director buys for quite some time now?
What, actually look out for the PI's? That would be very un-scancell like π. Think you're asking for a little bit too much there! π
Where is that quote from crumbs? Seen it a few times now. LGB?
Thanks Senza.
So it does seem like the forced seller here is linked to the merry go round of this Odey situation then?
Buttcrack, Professor Durrant categorically stated they are funded well into next year, plus likely Genmab payments, so your post RE dilution, is as ever complete and utter nonsense.
Like occams says, you need a show a bit more sophistication and maybe get a new deramping template, it's far too basic and too generic. Copy and paste will only get you so far.
The boiler room template.
Well someone sees value at these prices then.
I was trying to look into this last week, probably barking up the wrong tree but I found something on the Seneca VCT, but wasn't able to dig down into it.
" (The only inflections I have witnessed so far are downward ones : - ) )"
π You're not wrong. But joking aside, as I've said before, it almost feels intentional. I wonder if we will find out if some of the bigger buys last week were Diggle.
Fair enough WW, thanks.
WW - this isn't aimed neccesarialy at you but i'm a tad confused, wasnt the initial general concesus that the RNS last monday good to very good? (The interview on the other had was, in hindsight, plain bad).
Also just to clarify, did I read that you have sold most of your holding post the RNS so it would be fair to say you now have a somewhat different view of the company?
Another reason perhaps for splitting/separating RNS's, with well defined, more detailed RNS per topic.
I for one am enjoying the new cynical side of crumbs π
But in all seriousness what you say has a more than a hint of truth about it, sadly, so hopefully with the Crossery influence there is move fully to a commercial mindset, and move away from the academia mindset.
"Other biotechs with suitably skilled bod have done much bigger deals at earlier stages with less/worse results'"
douves nailed there for me... "
+1 RE douves comment.
"WTP thanks, It is exactly a feeling of the rug being pulled and me screaming not an effffin gain... more core holding has been over 100% up here after years of post modi discovery spike nibbling why oh why and how long this time and all those such things lol"
I think this is the crux of the issue for me as well, and i could have summarised my long post with just saying things have taken far far too long with Scancell to progress, or to commercialise 'anything', and when it does look like we might hit a turning point, they contrive, somehow to make things worse, especially for the SP, i.e. a rug pull.
Basically I think my patience as at the very edge.
...seems to have taken a keen interest on posts over here instead of his forum, and taken a role of offering a running commentary on our posts.
Whilst I regret not using TA/regret not being more pragmatic with my holding (now), this is all very very easy to say in hindsight. 2tyke is acting like the all seeing TA oracle, saying "i told you so ages ago", even though he only seemed to appeared on the other forum quite recently.
2tyke = captain hindsight.
Bore off please 2tyke, maybe stick to commenting on posts on your forum.
Just to add/edit:
RE Interview and funding comment, why did she not mention the Genmab payments/potential payments from them and/or other payments from other upcoming potential deals? I.e. it's not really a worry?
I'm hoping this all a moot point and that the "negativity" is all one big ruse to hide the fact there is gargantuan deal being worked on in the background hence the need to be coy/negative.
This is a long meandering post about this week.
Crumbs:
********
It says a lot when one of the most positive (but still IMO fair) posters gets that fed up. The company has so much promise, potential, and just when you think they turn a corner, somehow Scancell manage to pull the rug and bring down the share price. It is us LTH's who suffer. So no wonder Crumbs had had enough.
Interview:
**********
The questions that proactive asked who have been supplied by Scancell in advacnce to Proactive to ask, i.e. the answers would have needed to be prepped. So wWhy leave that particualr question til last, and why answer it in such a negative way/worse case scenario way?
Durrant - her business nous is clearly second fiddle to her science nous. Why didnt Crossey take part in the interview and answer the business type questions instead?
We saw the (delayed) SP reaction, which we can assume(?) was related to the interview.
There is a cynical part of me if that wonders how deliberate this is. I.e. "We don't want that SP to fly just yet, hold your horses". This is doubly emphsised by the continual dour RNS's with barely a hint of excitement.
E.g. "Encouraging early efficacy data from ModiFY trial"
Encouraging, whats wrong with positive, or even highly encouraging, which they actually used in their Linkedin.
And as mentioned, why did they not split the RNS's? Its like they deliberately want to stifle good news? It's actually bizzare!
Sepetember:
*************
If no significant news/uptick in price for the Sept conference I will likley be selling most of my significant holding, enough is enough.
Whilst I wouldnt nor couldnt influence others, I do think it is time we started talking with our feet.
As mentioned by others, PI's are clearly second fiddle, low priority to Scancell. Perhaps we need to be alot more vocal? Has anoyone emailed the compnay RE this week?
Scancell sometimes feels like that partner who never wants to commit and just keeps making promises!
But I know, if you don't like an investment, "just shut up and sell!". But that's the thing, there is insane potential here, I just wish they would capitalise on it.
LTH's:
This is apainful one for me to admit, but us LTH's were wrong, very wrong (obvious in hindsight)
However when you see the potential you can see why we had our hopes up, but the company seem to continuily mess up the potenial/opportunities, never fufilling it's potential, never exploiting the monetisation possibilities.
Techinical analysis, which I am appreciating more and more, would have, would have worked out better for most of us if followed. Instead of the "hold and hope" strategies most of us have been doing. Unfortualey us LTH are far too emotionally invested. Ironically, my other investments, I barely hold for more than few week/month at tops.
However of course, everything, especially in investing, is easy in hindsight.
But hey ho, what's just "another" two months I guess :-O
Another excellent post and analysis Johnnyb1.
The question is why did the RNS (and Prof Durrants interview) possibly underplay things?
IMO we saw the aftermath of what we think is a PI offloading.
The reason I ask is my broker is showing +8.43%.